Industry News
Teaching the Immune System to Recognize Pancreatic Cancer's Most Common Mutation
Nearly 9 in 10 cases of pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, are driven by mutations in a gene called KRAS. These mutations help cancer cells grow and survive, and they have long been one of the hardest targets in cancer research.
A new Mayo Clinic-led study offers an encouraging step forward. Researchers tested an investigational vaccine that targets seven of the most common KRAS mutations. The vaccine travels to the lymph nodes, where it helps T cells, the immune system's attackers, learn to identify cancer cells carrying mutated KRAS.
In the phase 2 trial, 144 patients who had already been treated with surgery and chemotherapy were randomly assigned to receive the vaccine or to observation. Of the 90 vaccinated patients who could be evaluated, 89 developed stronger T-cell responses against mutated KRAS. Researchers also saw the immune system begin recognizing other cancer-related targets not included in the vaccine, and the response held up over time.
What the study did not yet show is whether the vaccine helps patients stay cancer-free longer. A phase 3 trial is planned to answer that question.
Read the full article: Vaccine generates immune response to KRAS mutations in pancreatic cancer (Medical Xpress)
.png)
.png)














.png)






